Photobiomodulation for the Prevention of Radiation Induced Oral Mucositis

Inclusion Criteria: * Age ≥ 18 years of age * Willing and able to understand and sign informed consent form approved by the institutional review board (IRB) * Histological diagnosis of head and neck cancer of the oral cavity with no evidence of macroscopic residual disease post-surgery (R0 or R1 resection) and no gross residual lymphadenopathy in the planned PBM treatment area * Planned treatment with radiotherapy or chemoradiotherapy to a dose of ≥ 50 Gy * ECOG Performance Status of 0 or 1 * Intact oral mucosa (no visible ulceration, dehiscence or active infection Exclusion Criteria: * Gross macroscopic residual disease post surgery (R2 resection) or gross residual lymphadenopathy in the planned PBM treatment area * Prior radiotherapy to the Head and Neck including the oral or oropharyngeal mucosa. * Prior cytotoxic chemotherapy in the last 3 months * Diagnosis of photosensitive disorder (cutaneous porphyria, xeroderma pigmentosum, etc) * Concurrent administration of Cetuximab